Logo image of PVLA

PALVELLA THERAPEUTICS INC (PVLA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PVLA - US6979471090 - Common Stock

100.58 USD
-0.33 (-0.33%)
Last: 12/9/2025, 1:59:20 PM
Fundamental Rating

3

PVLA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. PVLA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PVLA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PVLA had negative earnings in the past year.
In the past year PVLA has reported a negative cash flow from operations.
In the past 5 years PVLA always reported negative net income.
PVLA had a negative operating cash flow in each of the past 5 years.
PVLA Yearly Net Income VS EBIT VS OCF VS FCFPVLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

PVLA has a Return On Assets (-52.39%) which is comparable to the rest of the industry.
With a Return On Equity value of -90.65%, PVLA perfoms like the industry average, outperforming 48.59% of the companies in the same industry.
Industry RankSector Rank
ROA -52.39%
ROE -90.65%
ROIC N/A
ROA(3y)-39.19%
ROA(5y)-36.56%
ROE(3y)-79.34%
ROE(5y)-89.63%
ROIC(3y)N/A
ROIC(5y)N/A
PVLA Yearly ROA, ROE, ROICPVLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PVLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PVLA Yearly Profit, Operating, Gross MarginsPVLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

5

2. Health

2.1 Basic Checks

PVLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PVLA has more shares outstanding
The number of shares outstanding for PVLA has been increased compared to 5 years ago.
PVLA has a worse debt/assets ratio than last year.
PVLA Yearly Shares OutstandingPVLA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
PVLA Yearly Total Debt VS Total AssetsPVLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

PVLA has an Altman-Z score of 22.40. This indicates that PVLA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 22.40, PVLA belongs to the top of the industry, outperforming 90.21% of the companies in the same industry.
PVLA has a Debt/Equity ratio of 0.41. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of PVLA (0.41) is worse than 71.37% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z 22.4
ROIC/WACCN/A
WACC8.78%
PVLA Yearly LT Debt VS Equity VS FCFPVLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

PVLA has a Current Ratio of 6.49. This indicates that PVLA is financially healthy and has no problem in meeting its short term obligations.
PVLA has a Current ratio of 6.49. This is in the better half of the industry: PVLA outperforms 66.67% of its industry peers.
A Quick Ratio of 6.49 indicates that PVLA has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.49, PVLA is doing good in the industry, outperforming 67.04% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.49
Quick Ratio 6.49
PVLA Yearly Current Assets VS Current LiabilitesPVLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.92% over the past year.
The Revenue for PVLA has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)68.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.12%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 24.88% on average over the next years. This is a very strong growth
PVLA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 586.68% yearly.
EPS Next Y-16.23%
EPS Next 2Y-12.93%
EPS Next 3Y-26.72%
EPS Next 5Y24.88%
Revenue Next Year-100%
Revenue Next 2Y64.9%
Revenue Next 3Y881.18%
Revenue Next 5Y586.68%

3.3 Evolution

PVLA Yearly Revenue VS EstimatesPVLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
PVLA Yearly EPS VS EstimatesPVLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 20 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PVLA. In the last year negative earnings were reported.
Also next year PVLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PVLA Price Earnings VS Forward Price EarningsPVLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PVLA Per share dataPVLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A cheap valuation may be justified as PVLA's earnings are expected to decrease with -26.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.93%
EPS Next 3Y-26.72%

More info and screens

0

5. Dividend

5.1 Amount

PVLA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PALVELLA THERAPEUTICS INC

NASDAQ:PVLA (12/9/2025, 1:59:20 PM)

100.58

-0.33 (-0.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11 2025-11-11/bmo
Earnings (Next)03-30 2026-03-30/amc
Inst Owners64.18%
Inst Owner Change44.26%
Ins Owners16.63%
Ins Owner Change0%
Market Cap1.19B
Revenue(TTM)N/A
Net Income(TTM)-35.07M
Analysts84.44
Price Target133.71 (32.94%)
Short Float %8.3%
Short Ratio3.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.13%
Min EPS beat(2)-20.45%
Max EPS beat(2)-13.81%
EPS beat(4)1
Avg EPS beat(4)-76.9%
Min EPS beat(4)-313.44%
Max EPS beat(4)40.1%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)61.37%
PT rev (3m)108.9%
EPS NQ rev (1m)-8.87%
EPS NQ rev (3m)-7.71%
EPS NY rev (1m)-6.76%
EPS NY rev (3m)-11.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 30.79
P/tB 30.79
EV/EBITDA N/A
EPS(TTM)-5.35
EYN/A
EPS(NY)-3.91
Fwd EYN/A
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-1.91
OCFYN/A
SpS0
BVpS3.27
TBVpS3.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.39%
ROE -90.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.19%
ROA(5y)-36.56%
ROE(3y)-79.34%
ROE(5y)-89.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.49
Quick Ratio 6.49
Altman-Z 22.4
F-Score3
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.12%
EPS Next Y-16.23%
EPS Next 2Y-12.93%
EPS Next 3Y-26.72%
EPS Next 5Y24.88%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y64.9%
Revenue Next 3Y881.18%
Revenue Next 5Y586.68%
EBIT growth 1Y-71.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-126.4%
EBIT Next 3Y-80.85%
EBIT Next 5Y36.37%
FCF growth 1Y52.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.02%
OCF growth 3YN/A
OCF growth 5YN/A

PALVELLA THERAPEUTICS INC / PVLA FAQ

What is the ChartMill fundamental rating of PALVELLA THERAPEUTICS INC (PVLA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PVLA.


What is the valuation status of PALVELLA THERAPEUTICS INC (PVLA) stock?

ChartMill assigns a valuation rating of 0 / 10 to PALVELLA THERAPEUTICS INC (PVLA). This can be considered as Overvalued.


How profitable is PALVELLA THERAPEUTICS INC (PVLA) stock?

PALVELLA THERAPEUTICS INC (PVLA) has a profitability rating of 1 / 10.